Tomas Forslund

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Jag är specialist i allmänmedicin med 20 års bred klinisk erfarenhet som omfattar kardiologi, internmedicin, onkologi, allmänpraktik och hemsjukvård.
Jag har läkarexamen och en doktorsexamen (PhD) i farmakoepidemiologi från Karolinska Institutet och är sedan 2014 medicinsk rådgivare åt Region Stockholm.
Jag är självlärd programmerare och författare till cirka 25 vetenskapliga artiklar, huvudsakligen observationell epidemiologisk forskning i stora datalager.

Forskningsbeskrivning

Hur kan du …
Vårdens genomförande
- förbättra implementeringen av nya riktlinjer?
- balansera följsamhet till riktlinjer med ett patientcentrerat perspektiv?
- anpassa riktlinjer för att hantera multimorbiditet och polyfarmaci?
- kombinera digital och fysisk vård på ett effektivt och säkert sätt?
Algoritmbaserad medicin
- gå från manuell handläggning av kroniska tillstånd till att automatiskt trigga algoritmer baserade på aktuella riktlinjer?
- kommunicera ordinerade mätningar, blodprover och remisser till patienter på ett effektivt sätt?
- automatisera patientspecifik information om sjukdom och behandling?
- tillhandahålla patientspecifik och relevant riskskattning samt beslutsstöd?
- automatisera generering av behandlingsplaner/patientkontrakt?

Artiklar

Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2025;81(5):739-753
Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region-a register-based cross-sectional study
Fors A; Forslund T; Sundstrom A; Wettermark B
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2025;34(1):e70075
Have People Treated With Antihypertensives Been Diagnosed With Hypertension? A Cross-Sectional Study in Stockholm, Sweden
Treciokiene I; Forslund T; Kahan T; Taxis K; Wettermark B
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2024;80(10):1571-1580
Statin treatment for primary and secondary prevention in elderly patients-a cross-sectional study in Stockholm, Sweden
Wettermark B; Kalantaripour C; Forslund T; Hjemdahl P
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023;32(11):1223-1232
Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries
Komen JJ; Hunt NB; Pottegard A; Hjemdahl P; Wettermark B; Olesen M; Bennie M; Mueller T; Carragher R; Karlstad O; Kjerpeseth LJ; Klungel OH; Forslund T
Article: EUROPEAN HEART JOURNAL. 2022;43(37):3528-3538
Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study
Komen JJ; Pottegard A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hallas J; Olesen M; Bennie M; Mueller T; Carragher R; Karlstad O; Kjerpeseth LJ; Klungel OH
Article: HEART. 2022;108(8):613-618
Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
Komen J; Pottegard A; Hjemdahl P; Mantel-Teeuwisse AK; Wettermark B; Hellfritzsch M; Hallas J; Herings R; Smits L; Forslund T; Klungel O
Article: EUROPACE. 2021;23(11):1722-1730
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries
Komen JJ; Pottegard A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hellfritzsch M; Hallas J; Olesen M; Bennie M; Mueller T; Voss A; Schink T; Haug U; Kollhorst B; Karlstad O; Kjerpeseth LJ; Klungel OH
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2021;10(16):e021716
Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation
Forslund T; Braunschweig F; Holzmann MJ; Siddiqui AJ
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021;30(7):934-951
Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study
Komen JJ; Belitser SV; Wyss R; Schneeweiss S; Taams AC; Pajouheshnia R; Forslund T; Klungel OH
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(F11):f72-f80
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
Komen JJ; Heerdink ER; Klungel OH; Mantel-Teeuwisse AK; Forslund T; Wettermark B; Hjemdahl P
Article: FAMILY PRACTICE. 2021;38(2):132-140
Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study
Forslund T; Carlsson AC; Ljunggren G; Arnlov J; Wachtler C
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(1):3-10
Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality
Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Article: BMC PSYCHIATRY. 2020;20(1):328
Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study
Forslund T; Kosidou K; Wicks S; Dalman C
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;107(1):287-294
Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding
Komen JJ; Hjemdahl P; Mantel-Teeuwisse AK; Klungel OH; Wettermark B; Forslund T
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2019;48(4):668-673
Venous thromboembolism 2011-2018 in Stockholm: a demographic study
Wandell P; Forslund T; Danin Mankowitz H; Ugarph-Morawski A; Eliasson S; Braunschwieg F; Holmstrom M
Journal article: EUROPEAN HEART JOURNAL. 2019;40(Supplement_1):ehz745.0020
3053High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic treatment
Komen JJ; Forslund T; Teeuwisse AKM; Klungel OH; Wettermark B; Von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Journal article: EUROPEAN HEART JOURNAL. 2019;40(Supplement_1):ehz745.1121
P4745Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study
Komen JJ; Hjemdahl P; Teeuwisse AKM; Klungel OH; Wettermark B; Forslund T
Article: STROKE. 2018;49(9):2122-2128
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience
Forslund T; Komen JJ; Andersen M; Wettermark B; von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
Journal article: EUROPEAN HEART JOURNAL. 2018;39(suppl_1):ehy565.1458
1458Improved stroke prevention in atrial fibrillation after the introduction of NOACs; the Stockholm experience
Forslund T; Komen JJ; Andersen M; Wettermark B; Von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
Article: EUROPACE. 2018;20(3):420-428
Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
Forslund T; Wettermark B; Andersen M; Hjemdahl P
Article: AMERICAN JOURNAL OF CARDIOLOGY. 2017;120(8):1302-1308
Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants
Loikas D; Forslund T; Wettermark B; Schenck-Gustafsson K; Hjemdahl P; von Euler M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2017;73(10):1315-1322
Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs
Komen J; Forslund T; Hjemdahl P; Wettermark B
Journal article: EUROPEAN HEART JOURNAL. 2017;38(suppl_1):ehx504.p3582
P3582Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences
Loikas D; Forslund T; Wettermark B; Schenck-Gustafsson K; Hjemdahl P; Von Euler M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2017;83(3):642-652
Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis
Komen J; Forslund T; Hjemdahl P; Andersen M; Wettermark B
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;72(3):329-338
Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation
Forslund T; Wettermark B; Hjemdahl P
Journal article: CIRCULATION. 2015;132(suppl_3)
Abstract 13898: Atrial Fibrillation And Persistence With Anticoagulant Treatment
Forslund T; Wettermark B; Hjemdahl P
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(12):1477-1485
Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA₂DS₂VASc scores: experience from the Stockholm region
Forslund T; Wettermark B; Wandell P; von Euler M; Hasselstrom J; Hjemdahl P
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2013;170(2):208-214
Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system
Forslund T; Wettermark B; Wandell P; von Euler M; Hasselstrom J; Hjemdahl P
Article: LAKARTIDNINGEN. 2011;108(36):1664-1665
[Say no to the extremes in the debate on lipid reduction].
Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Article: JOURNAL OF OBESITY. 2011;2011:459263-7
Usage, Risk, and Benefit of Weight-Loss Drugs in Primary Care
Forslund T; Raaschou P; Hjemdahl P; Krakau I; Wettermark B
Article: LAKARTIDNINGEN. 2010;107(13-14):910-913
[Anti-obesity agents do not seem to have any beneficial effects. Health centers prescribe preparations haphazardly, according to a medical records study].
Forslund T; Wettermark B; Raaschou P; Hjemdahl P; Krakau I
Article: LAKARTIDNINGEN. 2007;104(51-52):3879-3881
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].
Wettermark B; Raaschou P; Forslund T; Hjemdahl P
Visa fler

Alla övriga publikationer

Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2024;33:602-603
Application of Capture-Recapture Method to Estimate Prevalence With Registry Data
Giunta DH; Karlsson P; Forslund T; Wettermark B
Letter: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(3):e31
Themultiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? Response
Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:133-134
Non-vitamin K antagonist oral anticoagulant and proton-pump inhibitor cotreatment and the association with upper gastrointestinal bleeds in patients with atrial fibrillation: A multi-database cohort study
Komen J; Pottegard A; Forslund T; Mantel-Teeuwisse A; Wettermark B; Hellfritzsch M; Hallas J; Smits L; Herings R; Hjemdahl P; Klungel O
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:648-649
Long-term adherence and persistence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
Komen J; Heerdink R; Klungel O; Mantel-Teeuwisse A; Forslund T; Wettermark B; Hjemdahl P
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:637
Repeating greedy nearest neighbor caliper propensity score matching in the same cohort can yield highly inconsistent estimates of the exposure-outcome association: A simulation study
Komen J; Pajouheshnia R; Forslund T; Belitser S; Klungel O
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:2949
Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study
Komen JJ; Hjemdahl P; Mantel-Teeuwisse AK; Klungel OH; Wettermark B; Forslund T
Conference publication: EUROPEAN HEART JOURNAL. 2019;40:1848
High mortality in atrial fibrillation patients suffering ischemic stroke, intracranial hemorrhage or a gastrointestinal bleed and associations with the preceding antithrombotic treatment
Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; Wettermark B; Von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:206
Antithrombotic treatment preceding ischemic stroke, intracranial hemorrhage, and gastrointestinal bleeds and mortality in patients with atrial fibrillation
Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; Wettermark B; Hjemdahl P
Review: LAKARTIDNINGEN. 2018;115:FAH6
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
Hjemdahl P; Braunschweig F; Holmström M; Johnsson H; von Euler M; Wallén H; Forslund T
Conference publication: EUROPEAN HEART JOURNAL. 2018;39:271
Improved stroke prevention in atrial fibrillation after the introduction of NOACs; the Stockholm experience
Forslund T; Komen JJ; Andersen M; Wettermark B; Von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2018;27:8-9
Association between proton pump inhibitor use and gastrointestinal bleeds in NOAC-treated AF patients
Komen J; Forslund T; Wettermark B; Hjemdahl P; Klungel O; Mantel-Teeuwisse A
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2017;26:568-569
Factors Associated with Antithrombotic Treatment Decisions for Stroke Prevention in Atrial Fibrillation in the Stockholm Region After the Introduction of NOACs
Komen J; Forslund T; Hjemdahl P; Wettermark B
Conference publication: EUROPEAN HEART JOURNAL. 2017;38:765
Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences
Loikas D; Forslund T; Wettermark B; Schenck-Gustafsson K; Hjemdahl P; Von Euler M
Doctoral thesis: 2017
Antithrombotic treatment of atrial fibrillation before and after the introduction of non-vitamin K antagonist oral anticoagulants (NOAC) in the Stockholm health care region
Forslund T
Conference publication: EUROPEAN HEART JOURNAL. 2016;37:792
Stroke and bleeding with NOAC and warfarin in patients with non-valvular atrial fibrillation in the Stockholm healthcare system
Forslund T; Wettermark B; Hjemdahl P
Review: LAKARTIDNINGEN. 2015;112:CZYS
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Forslund T; von Euler M; Johnsson H; Holmström M; Wettermark B; Hjemdahl P
Conference publication: EUROPEAN HEART JOURNAL. 2014;35:293
Risks for stroke and bleeding with warfarin and aspirin in patients with atrial fibrillation at different CHA2DS2VASc-scores: Experience from the Stockholm region
Forslund T; Wettermark B; Wandell P; Von Euler M; Hasselstrom J; Hjemdahl P
Conference publication: EUROPEAN HEART JOURNAL. 2013;34(suppl_1):p4100
Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system
Forslund T; Wettermark B; Wandell P; Von Euler M; Hasselstrom J; Hjemdahl P
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:746
Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system
Forslund T; Wettermark B; Wandell P; Von Euler M; Hasselstrom J; Hjemdahl P
Other: LAKARTIDNINGEN. 2011;108(47):2444-2445
[Visions are good but the guidelines require evidence].
Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B

Forskningsbidrag

Utredning av kronisk kranskärlssjukdom i öppenvård (primärvård och specialiserad öppenvård)
Region Stockholm
Utredning av kronisk kranskärlssjukdom i öppenvård (primärvård och specialiserad öppenvård)
Region Stockholm
Randomiserad kontrollerad studie som utvärderar implementering av personcentrerat och sammanhållet vårdförlopp för hypertoni
Region Stockholm
Utredning och diagnostik av stabil kranskärlsjukdom i öppenvården (primärvård och specialiserad öppenvård)
Karolinska Institutet
Delfinansiering av doktorand inom allmänmedicin i Region Stockholm 2025

Anställningar

Anknuten till Forskning, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2024-2027

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2017
Läkarexamen, Karolinska Institutet, 2002

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI